Ioannis Kotsantis Selected Research

Ioannis Kotsantis Research Topics

Disease

15	Neoplasms (Cancer) 01/2023 - 01/2016
9	Squamous Cell Carcinoma of Head and Neck 01/2023 - 01/2016
8	Head and Neck Neoplasms (Head and Neck Cancer) 01/2023 - 01/2016
3	Sarcoma (Soft Tissue Sarcoma) 06/2022 - 01/2018
2	Osteosarcoma (Osteogenic Sarcoma) 01/2022 - 04/2021
2	Pain (Aches) 02/2021 - 01/2018
2	Breast Neoplasms (Breast Cancer) 11/2020 - 01/2020
2	Carcinoma (Carcinomatosis) 08/2020 - 01/2018
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 08/2020 - 08/2019
2	Neoplasm Metastasis (Metastasis) 01/2018 - 01/2018
1	Lung Neoplasms (Lung Cancer) 01/2023
1	Proteinuria 01/2023
1	Exanthema (Rash) 01/2023
1	Necrosis 01/2023
1	Glomerulonephritis 01/2023
1	Hematuria 01/2023
1	Mouth Neoplasms (Oral Cancer) 09/2022
1	Carcinogenesis 06/2022
1	Drug-Related Side Effects and Adverse Reactions 04/2022
1	Fever (Fevers) 01/2022
1	Pericarditis 01/2022
1	Chills 01/2022
1	Nasopharyngeal Carcinoma 12/2021
1	Adenocarcinoma 02/2021
1	Abdominal Pain (Pain, Abdominal) 02/2021
1	Pancreatic Neoplasms (Pancreatic Cancer) 02/2021
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 08/2020
1	Triple Negative Breast Neoplasms 08/2020
1	Lichen Planus (Lichen Ruber Planus) 01/2020
1	Oral Lichen Planus 01/2020
1	Disease Progression 01/2020
1	Stomach Neoplasms (Stomach Cancer) 01/2018
1	Clinical Deterioration 01/2018
1	Arthritis (Polyarthritis) 01/2018
1	Chondrosarcoma 01/2018

Drug/Important Bio-Agent (IBA)

6	Immune Checkpoint InhibitorsIBA 01/2023 - 01/2016
5	Biomarkers (Surrogate Marker)IBA 01/2023 - 01/2016
5	Cisplatin (Platino)FDA LinkGeneric 01/2023 - 01/2019
3	NivolumabIBA 12/2020 - 01/2020
2	Monoclonal AntibodiesIBA 01/2023 - 08/2020
2	atezolizumabIBA 01/2023 - 08/2020
2	Tyrosine Kinase InhibitorsIBA 06/2022 - 01/2018
2	CytokinesIBA 11/2020 - 01/2020
2	Messenger RNA (mRNA)IBA 01/2020 - 01/2020
2	pembrolizumabIBA 01/2020 - 01/2018
2	Formaldehyde (Formol)FDA Link 01/2020 - 01/2019
2	ParaffinIBA 01/2020 - 01/2019
1	Immunoglobulin G (IgG)IBA 01/2023
1	B7-H1 AntigenIBA 01/2023
1	Circulating Tumor DNAIBA 01/2023
1	durvalumabIBA 01/2023
1	Cell-Free Nucleic AcidsIBA 01/2023
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2023
1	DNA (Deoxyribonucleic Acid)IBA 01/2023
1	olaparibIBA 01/2023
1	Proteins (Proteins, Gene)FDA Link 06/2022
1	TrabectedinIBA 04/2022
1	Immunologic Factors (Immunomodulators)IBA 01/2022
1	mifamurtideIBA 01/2022
1	Analgesics (Analgesic Drugs)IBA 02/2021
1	copanlisibIBA 11/2020
1	PlatinumIBA 08/2020
1	Methotrexate (Mexate)FDA LinkGeneric 01/2020
1	Fluorouracil (Carac)FDA LinkGeneric 01/2020
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2020
1	Epirubicin (Ellence)FDA LinkGeneric 01/2020
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2020
1	ChemokinesIBA 01/2020
1	Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)IBA 01/2020
1	Insulin-Like PeptidesIBA 08/2019
1	Insulin-Like Growth Factor I (IGF-1)IBA 08/2019
1	Tumor Biomarkers (Tumor Markers)IBA 01/2019
1	Platelet-Derived Growth Factor beta Receptor (Receptor, Platelet Derived Growth Factor beta)IBA 01/2018
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2018
1	pazopanib FDA Link 01/2018
1	Growth Factor ReceptorsIBA 01/2018
1	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 01/2018
1	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 01/2018
1	Angiogenesis InhibitorsIBA 05/2017
1	Programmed Cell Death 1 ReceptorIBA 01/2016
1	CTLA-4 AntigenIBA 01/2016

Therapy/Procedure

10	Immunotherapy 01/2022 - 01/2016
4	Chemoradiotherapy 01/2023 - 01/2019
4	Therapeutics 04/2021 - 01/2018
3	Drug Therapy (Chemotherapy) 06/2022 - 01/2018
1	Aftercare (After-Treatment) 01/2023
1	Neck Dissection (Radical Neck Dissection) 09/2022
1	Adjuvant Chemotherapy 01/2022
1	Radiotherapy 01/2022
1	Radiofrequency Ablation 02/2021
1	Biological Therapy 01/2018